🇺🇸 FDA
Pipeline program

Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.

SOM230-RECAG-PK-612

Phase 1 other active

Quick answer

Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects. for Post-bariatric hypoglycaemia is a Phase 1 program (other) at Recordati Ireland with 1 ClinicalTrials.gov record(s).

Program details

Company
Recordati Ireland
Indication
Post-bariatric hypoglycaemia
Phase
Phase 1
Modality
other
Status
active

Clinical trials